GYPC antibody targets glycophorin C (GYPC), a sialoglycoprotein expressed on the erythrocyte membrane. As a member of the glycophorin family, GYPC plays a critical role in maintaining membrane structural integrity by linking the cytoskeleton to the lipid bilayer via protein 4.1R and p55. It carries the Gerbich (Ge) blood group antigens, with variants influencing susceptibility to Plasmodium falciparum malaria and associations with hereditary elliptocytosis. GYPC antibodies are clinically significant in transfusion medicine and hematology. Naturally occurring anti-Ge antibodies may cause hemolytic transfusion reactions or hemolytic disease of the fetus/newborn. Autoantibodies against GYPC are occasionally observed in autoimmune hemolytic anemia. In research, GYPC antibodies are utilized to study erythrocyte membrane disorders, malaria invasion mechanisms, and antigenic variations. Commercial GYPC antibodies typically recognize extracellular epitopes, aiding in blood group typing and biochemical characterization. Recent studies also explore GYPC's potential as a biomarker in certain cancers, expanding its investigative applications beyond hematology.